Miller David C, Sanda Martin G, Dunn Rodney L, Montie James E, Pimentel Hector, Sandler Howard M, McLaughlin William P, Wei John T
Department of Urology, University of Michigan Medical Center, Ann Arbor, MI, USA.
J Clin Oncol. 2005 Apr 20;23(12):2772-80. doi: 10.1200/JCO.2005.07.116.
We sought to elucidate long-term changes in health-related quality-of-life (HRQOL) outcomes by prospectively re-evaluating a well-characterized cohort of prostate cancer (PC) survivors 4 to 8 years after primary treatment.
Patients who had been evaluated previously at a median of 2.6 years after radical prostatectomy (RP), external radiation (three-dimensional conformal radiation therapy [3-D CRT]), or brachytherapy (BT) were recontacted at a median of 6.2 years after treatment. The clinical relevance of long-term HRQOL impairment among survivors was established by comparison with controls of similar age. Factors associated with HRQOL changes during this interval were evaluated.
Of the 964 eligible men, 709 (73.5%) completed measurable questionnaires. In four domains (urinary irritative-obstructive, urinary incontinence, bowel, and sexual), significant HRQOL differences were detected for at least one of the therapy groups, compared with controls (all P < .05). During the 4-year interval, significant improvement was observed for the urinary irritative-obstructive (P < .0001) and bowel (P < .0001) domains among BT patients, whereas urinary incontinence HRQOL worsened for both the BT (P = .0017) and 3-D CRT (P = .0008) treatment groups. Overall sexual HRQOL deteriorated for the 3-D CRT cohort (P = .0017), as well as for controls (P = .0136). Among RP patients, significant HRQOL changes were not observed.
During a 4-year interval from earlier to longer-term phases of PC treatment survivorship, sexual, urinary, and bowel dysfunction remain significant concerns among early-stage PC treatment survivors, compared with control men. Although postprostatectomy HRQOL remains relatively stable during this interval, disease-specific HRQOL continues to evolve among men treated with BT and 3-D CRT.
我们旨在通过对一组经过充分特征描述的前列腺癌(PC)幸存者在初次治疗后4至8年进行前瞻性重新评估,以阐明与健康相关的生活质量(HRQOL)结果的长期变化。
曾在前列腺癌根治术(RP)、外照射(三维适形放疗[3-D CRT])或近距离放疗(BT)后中位时间2.6年接受过评估的患者,在治疗后中位时间6.2年时再次被联系。通过与年龄相仿的对照组比较,确定幸存者中长期HRQOL损害的临床相关性。评估在此期间与HRQOL变化相关的因素。
在964名符合条件的男性中,709名(73.5%)完成了可测量的问卷。在四个领域(尿路刺激梗阻、尿失禁、肠道和性功能)中,与对照组相比,至少有一个治疗组检测到显著的HRQOL差异(所有P <.05)。在4年期间,BT患者的尿路刺激梗阻(P <.0001)和肠道(P <.0001)领域有显著改善,而BT(P =.0017)和3-D CRT(P =.0008)治疗组的尿失禁HRQOL均恶化。3-D CRT队列(P =.0017)以及对照组(P =.0136)的总体性功能HRQOL均恶化。在RP患者中,未观察到显著的HRQOL变化。
在PC治疗幸存者从早期到长期阶段的4年期间,与对照男性相比,性功能、尿路和肠道功能障碍仍是早期PC治疗幸存者的重要问题。虽然在此期间前列腺切除术后的HRQOL保持相对稳定,但接受BT和3-D CRT治疗的男性中,疾病特异性HRQOL仍在继续演变。